Kaida BioPharma

Funding and NIH signals

• SEC Form D raise Form D reports $1.6M sold since 2023 (filed Jan 21, 2026; amended Sep 1, 2026). SEC Form D 0001493152-26-003028 (Jan 21, 2026)
  Evidence (1 event)

  • Jan 21, 2026 · SEC Form D 0001493152-26-003028
    Name of Issuer: Kaida BioPharma Inc.; CIK: 1973954; Address: Fort Lauderdale, FL; Submission type: D; Filing date: 2026-01-21; Industry Group: Biotechnology; Date of First Sale: 2023-10-24; Types of Securities Offered: Equity; Business combination transaction: false; Total Offering Amount: 3000000; Total Amount Sold: 1570507; Federal exemptions: 06b || Name of Issuer: Kaida BioPharma Inc.; CIK: 1973954; Address: Fort Lauderdale, FL; Submission type: D/A; Filing date: 2026-09-01; Industry Group: Biotechnology; Date of First Sale: 2023-10-24; Types of Securities Offered: Equity; Business combination transaction: false; Total Offering Amount: 4100507; Total Amount Sold: 1600507; Federal exemptions: 06b

Job counts as of Oct 18, 2026. All funding and NIH signals